Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Health Educ Q ; 15(3): 241-57, 1988.
Article in English | MEDLINE | ID: mdl-3056874

ABSTRACT

Aptitude x treatment interaction (ATI) has been used only rarely in patient education research. This research paradigm incorporates individual differences (aptitudes) into experimental studies exploring differences in information strategies (treatments). ATI has great potential for applications to patient education research. It identifies patient characteristics and optimal instructional treatments, it is compatible with psychological theories and clinical approaches alike, and it offers a specific methodology for approaching existing problems in a new way. This article presents studies in which ATI has illuminated specific patient needs and treatments, and suggested further applications. Three studies (in addition to those reviewed) are examined in depth. One study determined general guidelines for designing instructional literature to accompany medication (drug package inserts), that would satisfy the requirements of a group of patients with varied reading ability. Another study examined the effect of patients' "prior knowledge" on their participation in a health education program. A third study explored the interaction between patients' view of self-control over their health and the use of different media for health-care instruction. Guidelines and considerations for conducting further ATI-based research are presented and discussed.


Subject(s)
Aptitude , Patient Education as Topic/methods , Patient Participation , Research Design , Humans , Psychometrics , Regression Analysis
2.
Clin Pharmacol Ther ; 41(4): 368-70, 1987 Apr.
Article in English | MEDLINE | ID: mdl-3829575

ABSTRACT

For 55 individual drugs, the time required for approval of the original new drug application (NDA) was compared with the time required for approval of supplemental NDAs. The mean time required for the original NDAs was 22.2 +/- 18.1 months; the mean for review of all 46 follow-on indications was similar (19.1 +/- 17.9 months). Since subsequent applications do not ordinarily require new assessment of clinical safety or animal toxicity studies, one would expect the subsequent applications to be processed more expeditiously. Such is not the case. The negative implications of these facts are discussed.


Subject(s)
Drug Evaluation , United States Food and Drug Administration , Time Factors , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...